Microbiological toxicity of Tilmicosin (cas 108050-54-0) on human colonic microflora in chemostats
-
Add time:08/24/2019 Source:sciencedirect.com
To evaluate the microbiological safety of Tilmicosin (cas 108050-54-0) on human intestinal microflora, four chemostat models of healthy human colonic ecosystems were exposed to tilmicosin (0, 0.436, 4.36, and 43.6 μg/mL) for 7 days. Prior to and during drug exposure, three microbiological endpoints were monitored daily including short-chain fatty acids, bacterial counts and macrolide susceptibility. Colonization resistance of each community was determined by 3 successive daily challenges of Salmonella typhimurium. Genes associated with virulence and macrolide resistance in Enterococcus faecalis were determined by PCR. Transcriptional expression of the virulence gene (gelE) in E. faecalis was determined by real-time RT-PCR. Our results showed that different concentrations of tilmicosin did not disrupt the colonization resistance in each chemostat. During exposure to 4.36 and 43.6 μg/mL tilmicosin, the Bacteroides fragilis population was significantly decreased while the proportion of resistant Enterococci increased. After long-term exposure to the highest concentration (43.6 μg/mL) of tilmicosin, the gelE gene was significantly up-regulated in the high-level macrolide resistant strains that also contained the ermB resistance gene. This study was the first of its kind to evaluate the microbiological toxicity of tilmicosin using a chemostat model. These findings also provide new insight into the co-occurrence of macrolide resistance and virulence in E. faecalis under tilmicosin selective pressure.
We also recommend Trading Suppliers and Manufacturers of Tilmicosin (cas 108050-54-0). Pls Click Website Link as below: cas 108050-54-0 suppliers
Prev:Minimum ignition energy of medicinal powder – Florfenicol and Tilmicosin (cas 108050-54-0)
Next:Microstructure and antioxidative capacity of the microalgae mutant Chlorella PY-ZU1 during Tilmicosin (cas 108050-54-0) removal from wastewater under 15% CO2) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original ResearchEffects of Tilmicosin (cas 108050-54-0) Phosphate Administration on Echocardiographic Parameters in Healthy Donkeys (Equus asinus): An Experimental Study08/29/2019
- Effects of nasal instillation of a nitric oxide-releasing solution or parenteral administration of Tilmicosin (cas 108050-54-0) on the nasopharyngeal microbiota of beef feedlot cattle at high-risk of developing respiratory tract disease08/28/2019
- Astragalus polysaccharides alleviate Tilmicosin (cas 108050-54-0)-induced toxicity in rats by inhibiting oxidative damage and modulating the expressions of HSP70, NF-kB and Nrf2/HO-1 pathway08/27/2019
- ResearchEffects of oral Tilmicosin (cas 108050-54-0) on health and performance in newly received beef heifers08/26/2019
- Microstructure and antioxidative capacity of the microalgae mutant Chlorella PY-ZU1 during Tilmicosin (cas 108050-54-0) removal from wastewater under 15% CO208/25/2019
- Minimum ignition energy of medicinal powder – Florfenicol and Tilmicosin (cas 108050-54-0)08/23/2019
- Preparation and evaluation of Tilmicosin (cas 108050-54-0) microspheres and lung-targeting studies in rabbits08/22/2019
- Removal of combined antibiotic (florfenicol, tylosin and Tilmicosin (cas 108050-54-0)) during anaerobic digestion and their relative effect08/21/2019